Aurobindo gets USFDA nod to market mental illness drug

Aurobindo Pharma has received US health regulator's approval to market generic version of AbbVie

RELATED ARTICLES

Inc's Depakote ER extended-release tablets, used for treating mental illness, in the American market.

The company has received final approval from US Food and Drug Administration (USFDA) to manufacture and market Divalproex Sodium Extended-release tablets in strengths of 250mg and 500mg, Aurobindo Pharma said in a statement today.

The Hyderabad-based firm said the "product is ready for launch".

Divalproex Sodium Extended-release tablets are indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features.

As per IMS sales data, the product had a market size of around USD 690 million for the twelve months ended March 2014.

The company said the product has been approved out of its Unit VII (SEZ) formulation facility in Hyderabad. It now has a total of 194 abbreviated new drug application (ANDA) approvals from the USFDA.

Aurobindo shares were trading at Rs 626.95 apiece on the BSE, down 1.93 per cent from its previous close.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Child abuse needs to be tackled with the seriousness it deserves

    The Bangalore rape case has again brought into focus an issue we Indians forever shy away from facing up to — child sexual abuse.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Varun Dutt

<b>Riskfactor</b>: THE BASE RATE BIAS

Base rate fallacy, also called base rate neglect or base ...

Parvez Imam

Revisiting history can do us all good

We often think that we understand history. We read it ...

Bubbles Sabharwal

Your happiness doesn’t depend on your needs

They are two different words (and even worlds) altogether: having ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture